Effects of Protein–Ligand Interactions on Hydrogen/Deuterium Exchange Kinetics: Canonical and Noncanonical Scenarios

Abstract

Hydrogen/deuterium exchange (HDX) methods are widely used for monitoring protein-ligand interactions. This approach relies on the fact that ligand binding can modulate the extent of protein structural fluctuations that transiently disrupt hydrogen bonds and expose backbone amides to the solvent. It is commonly observed that ligand binding causes a reduction of HDX rates. This reduction can be restricted to elements adjacent to the binding site, but other regions can be affected as well. Qualitatively, ligand-induced HDX protection can be rationalized on the basis of two-state models that equate structural dynamics with global unfolding/refolding. Unfortunately, such models tend to be unrealistic because the dynamics of native proteins are dominated by subglobal transitions and local fluctuations. Ligand binding lowers the ground-state free energy. It is not obvious why this should necessarily be accompanied by a depletion of excited-state occupancies, which would be required for a reduction of HDX rates. Here, we propose a framework that implies that ligand binding can either slow or accelerate amide deuteration throughout the protein. These scenarios are referred to as "type 1" and "type 2", respectively. Evidence for type 1 binding is abundant in the literature, whereas the viability of type 2 interactions is less clear. Using HDX mass spectrometry (MS), we demonstrate that the oxygenation of hemoglobin (Hb) provides a dramatic example of a type 2 scenario. The observed behavior is consistent with cooperative T → R switching, where part of the intrinsic O2 binding energy is reinvested for destabilization of the ground state. This destabilization increases the Boltzmann occupancy of unfolded conformers, thereby enhancing HDX rates. Surprisingly, O2 binding to myoglobin (Mb) also induces elevated HDX rates. These Mb data reveal that type 2 behavior is not limited to cooperative multisubunit systems. Although enhanced protection from deuteration is widely considered to be a hallmark of protein-ligand interactions, this work establishes that an overall deuteration increase also represents a viable outcome. HDX-based ligand screening assays, therefore, have to allow for canonical as well as noncanonical effects.

Using hydrogen deuterium exchange mass spectrometry to engineer optimized constructs for crystallization of protein complexes: Case study of PI4KIIIβ with Rab11

“…While these removed disordered regions likely play key biological roles,4 their presence greatly hampers attempts for high resolution structural studies. HDX‐MS has also been extensively used for mapping protein‐protein interfaces, and conformational changes induced by either protein or small molecule binding partners 39, 40, 41. A major advantage of using HDX‐MS in tandem with high resolution approaches is that the information on conformational dynamics of protein complexes provided by HDX‐MS allows for the design of an optimized strategy to design novel constructs of these complexes.…”

ApoE: In Vitro Studies of a Small Molecule Effector

“…Protein structural information can be coupled to mass shift and detected by mass spectrometry. The protein backbone amide HDX reports on solvent accessibility and hydrogen-bond networking (46–48), characterizing conformational changes induced by small molecule ligand binding (49). …”

HDX-MS guided drug discovery: small molecules and biopharmaceuticals

“…Differential HDX-MS is a well-suited approach for interrogating the alterations in protein conformation induced by small molecule ligand binding [24]. The pharmacology of ligands have traditionally been categorized as agonists, partial agonists, antagonists, and inverse agonists depending on whether they fully or partially activate, block, or repress a protein's activity.…”